Karyopharm Therapeutics (Nasdaq: KPTI) is to sell its investigational oral SINE compound KPT-350 to fellow Massachusetts-based biotech firm Biogen (Nasdaq: BIIB) in a deal worth up to $217 million.
SINE compounds are a family of small-molecule drugs that inhibit certain processes, resulting in reduced inflammation and neurotoxicity, and increased neuroprotective responses.
Lead candidate KPT-350 is a potential therapy for amyotrophic lateral sclerosis (ALS).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze